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Abstract
In radically resected gastric cancer the possibility to predict the site of relapse could be clinically relevant for the selection of
post-surgical management. We previously showed that specific tumour integrins genotypes are independently associated
with either peritoneal or hematogenous metastases (ITGA and ITGV). Recently VEGF and VEGF-R polymorphisms have been
demonstrated to potentially affect tumour angiogenesis and the metastatic process in gastric cancer. We then investigated
the role of VEGFs and VEGF-R genotyping in determining either peritoneal carcinosis or hematogenous metastases in
radically resected gastric cancer patients. Tumour genotyping for integrins (ITGA and ITGV) was also performed according to
our previous findings. Genotyping for VEGF-A, VEGF-C, VEGFR-1,2,3 and ITGA and ITGV was carried out on pT4a radically
resected gastric tumours recurring with either peritoneal-only carcinosis or hematogenous metastases. 101 patients fulfilled
the inclusion criteria: 57 with peritoneal carcinomatosis only and 44 with hematogenous spread only. At multivariate
analysis, intestinal histology and the AC genotype of rs699947 (VEGFA) showed to independently correlate with
hematogenous metastases (p = 0.0008 and 0.008 respectively), whereas diffuse histology and the AA genotype of rs2269772
(ITGA) independently correlated with peritoneal-only diffusion (p =,0.0001 and 0.03 respectively). Our results seem to
indicate that combining information from genotyping of rs699947 (VEGFA, AC), rs2269772 (ITGA, AA) and tumour histology
could allow clinicians to individuate gastric cancer at high risk for recurrence either with peritoneal or hematogenous
metastases. The selection tool deriving from this analysis may allow an optimal use of the available treatment strategies in
these patients.
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Introduction
The global outcome for radically resected gastric cancer patients
remained substantially unchanged across the years in western
Countries, with a 5-years survival rate ranging between 15% and
35% of all cases [1,2]. Despite multiple efforts, most clinical trials
investigating the role of post-operative treatments showed
controversial results.
In western Countries only a modest survival benefit, has been
observed for adjuvant chemotherapy mainly in pooled analyses
and the beneficial effect of chemoradiotherapy seemed limited to
patients receiving an inadequate clearance of the lymphatics [3,4].
Peritoneal carcinosis may be the first site of relapse in
approximately 40 to 50% of patients undergoing radical resection
[5,6,7]. Based on these data a potential role for intraperitoneal
chemotherapy in the prevention of peritoneal carcinomatosis has
been hypothesized [6,7]. However the containment of disease with
a locoregional treatment may be inadequate in patients at high risk
for hematogenous metastases and should be better reserved only to
those likely to recur in the peritoneum without hematogenous
diffusion. Unfortunately predictive factors for the site of recurrence
and potentially able to suggest a personalized post-operative
strategy are largely lacking. Although many clinical determinants
have been analyzed in the past, only few of them proved to be
effectively relevant in predicting the site of relapse. Clinical and
pathological factors such as tumour serosal involvement, tumour
histology (diffuse vs. intestinal), the extent of lymphadenectomy
and the presence of tumour cell in peritoneal lavage during
laparotomy have been indicated as predictive for the site of
recurrence in gastric cancer [4,8,9].
In a previous analysis we found that Genotyping of rs2269772
(ITGA) and rs11902171 (ITGV) may represent a critical asset in the
definition of high risk gastric cancer patients for peritoneal
carcinosis [10].
The Vascular Endothelial Growth Factors (VEGF) superfamily
has been identified to critically influence angiogenesis in solid
tumours. Published data suggest that in presence of tumour
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angiogenesis-related factors distant metastases are more likely to
occur [11,12].
Interestingly it has been also demonstrated that the angiogenic
phenotype may differ between intestinal-type and diffuse-type
gastric cancer. In different analyses intestinal-type tumours seem
in fact more biologically dependent on angiogenesis than diffuse-
type tumours [13,14,15].
Single-nucleotide polymorphisms (SNPs) in the vascular endo-
thelial growth factors (VEGF) and VEGF receptors (VEGF-R)
genes have been correlated to tumour neoangiogenesis through
different biological mechanisms. In patients with colorectal cancer
specific SNPs in the VEGF-R2 have been shown to significantly
influence microvessel density [16]. Specific SNPs in the VEGFA
gene resulted able to determine response to chemotherapy through
modulation of tumour blood vessels structure and function [17].
Tumour lymphangiogenesis is strictly dependent on the bi-
ological activity of the VEGFC and the VEGF-R3 [18,19].
Interestingly lymphatic diffusion along with direct colonization of
cancer cells also represent crucial, but biologically distinct, steps
for peritoneal dissemination. Based on these assumptions we can
then hypothesise that the altered expression of the VEGFC/
VEGFR-3 pathway may influence peritoneal diffusion of cancer
cells through the lymphatics [20]. On the other hand the
VEGFC/VEGF-R3 pathway has been also demonstrated relevant
for hematogenous cancer dissemination as well [21].
Predicting the location of recurrence amongst high risk
individuals may allow for tailored adjuvant approaches. We
therefore examined the role of tumour VEGFs and VEGF-Rs
polymorphisms in determining either peritoneal carcinosis or
hematogenous metastases in radically resected gastric cancer
patients. Clinical data and SNPs results for tumour VEGFs,
VEGF-Rs and integrins have been analysed with the aim to
suggest a biologically-driven profile to be employed as a tool for
the appropriate treatment selection in the appropriate patient.
Methods
Patients Selection
The patients study population was selected from a central
database including patients affected by gastric cancer, operated in
four different Institutions of our Region. Classification of the T, N
and M-factors was made according to the numeric system
introduced by the 7th TNM.
Only patients who had recurred within 2 years, with either
peritoneal-only carcinosis or hematogenous metastases after
curative gastrectomy for a pT4a gastric adenocarcinoma, who
did not receive adjuvant chemotherapy and whose tumour
specimen was available were selected for tumour genotyping.
Patients with either distant metastases at the time of diagnosis or
presence of exfoliated tumour cells in peritoneal lavage obtained
during laparotomy were excluded from analysis. We decided to
restrict our analysis to patients with pT4a tumours as this group of
patients is at higher risk for peritoneal diffusion and is often
considered for locoregional treatment such as intraperitoneal
chemotherapy. However a not negligible proportion of these
patients does not recur locally and therefore a selection tool in this
setting would be a particularly valuable asset for the treating
physicians. Since most recurrences are registered within 2 years
from diagnosis we chose to exclude patients recurring after this
time period in order to obtain an homogenous population.
Follow-up of both groups (peritoneal-only or hematogenous
metastases) occurred at three-months intervals. Follow-up con-
sisted of physical examination, a complete blood count, chest
radiography and US of the abdomen or CT scanning as clinically
indicated. The site and date of first relapse and the date of death
were recorded.
Ethics Statement
This study was approved by Ethical committee AOU Ospedali
Riuniti – Umberto I of our institution. All patients provided
informed written consent.
Tumour VEGF and VEGF-R Genotyping
VEGF and VEGF-R genotyping was performed on formalin-
fixed paraffin-embedded tissue block (about 30 mg) of primary
gastric cancer samples.
Paraffin wax was removed with xylene and the samples were
washed twice with 100% ethanol. DNA was isolated from the
deparaffinised tissue using the RecoverAllTM Total Nucleic Acid
Isolation Kit for FFPE Tissues (Applied Biosystems, Foster City,
CA, USA), according to the manufacturer’s instructions. DNA
from each sample was then eluted in 120 ml of eluting solution.
Single nucleotide polymorphisms (SNPs) within each gene were
selected using the Pupasuite software (http://pupasuite.bioinfo.
cipf.es/index.jsf - version 2.0.0, bioinfo 2008), the CIPF Single
Nucleotide Polymorphism database (dbSNP) generated by the
National Center for Biotechnology Information (http://www.ncbi.
nlm.nih.gov/SNP) and by review of the medical literature, using
the following criteria:
1) the polymorphism had some degree of likelihood to alter the
structure or the expression of the gene in a biologically
relevant manner (i.e. affecting ese sequences, 39 UTR or
promoter region);
2) the minor allele frequency was above 10% (with the only
exception of rs2305948, rs6877011 and rs307822);
3) the genetic polymorphism was established and well-docu-
mented.
Further considerations drove the selection of SNPs for our
study. A correlation between the presence of a specific allele on
a polymorphic site and the expression of the respective protein has
been previously documented for VEGF [22,23]. SNPs in
regulatory sequences, such as introns and 59 and 39 UTRs, have
been shown to alter mRNA stability [24,25] processing efficiency
[26], isoform expression [27,28] and localization [29]. Moreover,
regulatory motif sequences within the 39 UTR of mRNAs have
been shown to affect the stability of the messenger and/or its
translational efficiency [28]. Thus, it can be argued that SNPs in
these sequences may influence VEGF and VEGF-R gene
expression. Also on these bases, we selected the SNPs known to
affect VEGF and VEGF-R expression and those located in
regulatory sequences, for which a putative role in protein
regulation can be assumed.
Globally we assumed that selected SNPs had impact on protein
expression and therefore on biological function.
Selected SNPs were as follows: six polymorphisms in the
VEGFA gene (rs10434, G.A; rs2010963, G.C; rs25648, C.T;
rs3025039, C.T; rs699947, A.C; rs833061, C.T), two in
VEGFC (rs4604006, T.C; rs7664413, C.T), two in VEGF-R1
(FLT1) (rs664393, G.A; rs7993418, A.G), four in VEGF-R2
(KDR) (rs1870377, A.T; rs2071559, A.G; rs2305948, G.A;
rs7667298, A.G) and three in VEGF-R3 (FLT4) (rs307805,
A.G; rs6877011, C.G; rs307822, G.A). Chromosomal loca-
tions, positions and biological effects of investigated VEGF and
VEGFR SNPs have been summarised in table 1.
SNP genotyping was performed by TaqMan technology, using
SNP genotyping products (Applied Biosystems). Polymerase chain
VEGF in Metastatic Process in Gastric Cancer
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reaction (PCR) was performed and genotypes were analysed on
the 7300 Real-Time PCR System (Applied Biosystems) using an
ABI Prism 7300 Sequence Detection System software (version
1.3.1, Applied Biosystems). Each reaction contained 0.2 ml of total
genomic DNA. Genotyping was performed by laboratory person-
nel blinded to patient status, and a random 10% of the samples
were repeated to validate genotyping procedures.
All SNPs genotyped had to present an overall call rates of
$90% to be included in our analysis.
Tumour Integrins Genotyping
Genotyping for tumour integrins independently associated with
either peritoneal or hematogenous metastases in our previous
analysis (A and G genotypes of rs2269772, ITGA and G and C
genotypes of rs11902171, ITGV) was conducted as previously
described [10].
Statistical Analysis
Statistical analysis was performed with the MedCalc software
version 10.4.8 for Windows. The association between categorical
variables was estimated by Chi-square test. Logistic regression
analysis was used to assess the independent role of variables
resulted significant at univariate analysis.
Tested variables included sex (male vs. female), age (,65 yrs vs.
$ 65 yrs), absence or presence of lymph node metastases (pN0 vs.
pN+), type of lymphadenectomy (D1 vs. D2), tumour histology
according to Lauren’s classification (intestinal vs. diffuse), lym-
phatic/blood vessels invasion (presence vs. absence), the clinical
Center where surgery was performed, integrins genotyping (A and
G genotypes of rs2269772, ITGA and G and C genotypes of
rs11902171, ITGV) and each VEGF and VEGF-R polymorphism.
The ratio of the odds of the outcome (Odds ratio) in the 2
groups (peritoneal carcinosis only and hematogenous metastases)
was calculated with a 95% confidence interval. A significant level
of 0.05 was chosen to assess the statistical significance.
All polymorphisms were examined for deviation from Hardy-
Weinberg equilibrium using the Powermarker v. 3.25 package
(www.statgen.ncsu.edu/powermarker).
Linkage Disequilibrium (LD) analysis was also performed using
the Powermarker v. 3.25 package (www.statgen.ncsu.edu/
powermarker). LD was estimated using r2, with r2= 1 indicating
complete LD and r2= 0 indicating absent LD.
Results
Hardy-Weinberg Equilibrium and Linkage Disequilibrium
The frequencies of the tested genotypes resulted comparable to
those reported in Caucasians, with no significant deviation from
the Hardy-Weinberg equilibrium.
Linkage disequilibrium was not observed for the tumour
genotypes independently correlated with either peritoneal or
hematogenous metastases.
Patients Characteristics
One hundred and one patients were available for our analysis:
66 males and 35 females with a median age at diagnosis of 67
years (range 34–89). Follow-up data were available for all patients
included. Follow-up consisted of physical examination, a complete
blood count, chest radiography and US of the abdomen or CT/
MRI scanning as clinically indicated. Only patients who exclu-
sively developed either peritoneal carcinosis or hematogenous
metastases during the entire course of their disease were
considered.
Table 1. Chromosomal locations, positions and biological effects of investigated gene SNPs.
SNP ID Gene Chr Chr. Position Position in the gene/Effect Codon exchange aa. exchange
rs10434 VEGFA 6 43753212 39UTR – –
rs2010963 VEGFA 6 43738350 59UTR – –
rs25648 VEGFA 6 43738977 Syn; ESE TCC ) TCT S [Ser] ) S [Ser]
rs3025039 VEGFA 6 43752536 39UTR – –
rs699947 VEGFA 6 43736389 promoter – –
rs833061 VEGFA 6 43737486 promoter – –
rs4604006 VEGFC 4 177608775 intronic – –
rs7664413 VEGFC 4 177608707 intronic – –
rs664393 FLT1 13 29071001 39UTR – –
rs7993418 FLT1 13 28883061 Syn; ESE TAC ) TAT Y [Tyr] ) Y [Tyr]
rs1870377 KDR 4 55972974 Missense Subs. CAA ) CAT Q [Gln] ) H [His]
rs2071559 KDR 4 55992366 Init. Transcription – –
rs2305948 KDR 4 55979558 Missense Subs. GTA ) ATA V [Val] ) I [Ile]
rs7667298 KDR 4 55991731 59UTR – –
rs307805 FLT4 5 180077487 Prom; TFBS – –
rs6877011 FLT4 5 180029471 39UTR – –
rs307822 FLT4 5 180028717 39UTR – –
syn: Synonymous substitution;
ESE: Exon Splicing Enhancer;
39UTR: Untranslated Region 39UTR;
59UTR: Untranslated Region 59UTR;
Prom: Promoter region;
TFBS: Predicted Trascription Factor Binding Site.
doi:10.1371/journal.pone.0038192.t001
VEGF in Metastatic Process in Gastric Cancer
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e38192
All patients underwent radical surgery (R0) for pT4a gastric
cancer, regional lymphnodes were negative for metastases (pN0) in
23 patients (23%). Most of the patients underwent a D2
lymphadenectomy (94 cases, 93%). Pathology report showed
intestinal histology in 51 cases (51%) and diffuse histology in 50
patients (49%) (table 1). Fifty-seven patients (56%) developed
peritoneal carcinosis-only tumour diffusion, whereas hematoge-
nous metastases were diagnosed in the remaining 44 patients
(44%). Clinicopathological variables of both groups (carcinosis-
only and hematogenous metastases) were comparable with the
exception of tumour histology. All major clinical and pathological
characteristics are summarized in table 2.
Tumour VEGF and VEGF-R Genotyping
All SNPs genotyped presented an overall call rates of $90%.
Repeated samples for genotyping validation confirmed results
obtained by previous analysis in all cases.
Gastric tumours showing the AA genotype of rs10434 (VEGFA),
the AC genotype of rs699947 (VEGFA) and the GG genotype of
rs7993418 (FLT1) resulted more prone to hematogenous metas-
tases (peritoneal carcinosis vs. hematogenous metastases: 8% vs.
27%, p= 0.02; 30% vs. 59%, p= 0.006 and 2% vs. 16%, p= 0.02
respectively) (table 3). No correlation could be found between
these tumour genotypes and peritoneal-only diffusion.
Analysis of the remaining VEGF and VEGF-R polymorphisms
did not show any correlation with either peritoneal carcinosis or
hematogenous metastases (table 4).
Tumour Integrins Genotyping
Globally results for tumour integrins genotyping confirmed our
previous findings.
Patients tumours with the GG genotype of rs2269772 (ITGA)
resulted less prone to peritoneal carcinosis (peritoneal carcinosis vs.
hematogenous metastases: 39% and 77% of patients respectively,
p = 0.002), whereas the AA genotype of rs2269772 (ITGA) was
more frequently associated to peritoneal carcinosis (peritoneal
carcinosis vs. hematogenous metastases: 25% and 5% of patients
respectively, p = 0.014). The CC genotype of rs11902171 (ITGV)
was more frequently associated to peritoneal carcinosis (peritoneal
carcinosis vs. hematogenous metastases: 21% and 5% of patients
respectively, p = 0.016). On the contrary, patients with the GG
genotype of rs11902171 in the ITGV gene developed peritoneal
carcinosis less frequently than hematogenous metastases (perito-
neal carcinosis vs. hematogenous metastases: 42% and 66% of
patients respectively, p= 0.02).
Other Clinical/pathological Factors
Among the other tested variables, tumour diffuse histology
showed a correlation with peritoneal carcinosis (peritoneal
carcinosis vs. hematogenous metastases: 81% and 9% of patients
respectively, p,0.001), whereas tumour intestinal histology was
linked to hematogenous metastases (peritoneal carcinosis vs.
hematogenous metastases: 19% and 91% of patients respectively,
p,0.001) (table 2).
Multivariate Analysis
At multivariate analysis, intestinal histology and the AC
genotype of rs699947 (VEGFA) showed to independently correlate
with hematogenous metastases, whereas diffuse histology and the
AA genotype of rs2269772 (ITGA3) independently correlated with
peritoneal-only diffusion (p = 0.001). Odds ratio results for these
latter factors confirmed their role in guiding tumour cells through
Table 2. Patients characteristics.
Patients
Peritoneal carcinosis Hematogenous metastases p
N 57 44
Age (range) 63 (37–89) 61 (34–88)
Sex, n (%) n.s.
Males 33 (58) 33 (75)
Females 24 (42) 11 (25)
Stage at diagnosis, n (%) n.s.
pT4a pN0 9 (16) 14 (32)
pT4a pN+ 48 (84) 30 (68)
pN1 23 (40) 17 (39)
pN2 18 (32) 12 (27)
pN3 3 (5) 1 (2)
Tumour histology, n (%) ,0.0001
Intestinal 11 (19) 40 (91)
Diffuse 46 (81) 4 (9)
Lymphatic/blood vessels invasion, n (%) n.s.
Present 9 (16) 6 (14)
Absent 48 (84) 38 (86)
Lymphadenectomy, n (%) n.s.
D1 5 (9) 3 (7)
D2 52 (91) 41 (93)
doi:10.1371/journal.pone.0038192.t002
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the metastatic process toward the peritoneum or hematogenous
sites (table 5).
Discussion
The introduction of multiple therapeutic options for the post-
surgical management of radically resected gastric cancer patients
has opened the question of optimal patients selection. Un-
fortunately a critical limiting factor for the potential of these
treatment choices is represented by the lacking of clinical and
biological factors able to predict the site of recurrence. The
containment of disease with a locoregional treatment such as
intraperitoneal chemotherapy may be in fact inadequate in
patients at high risk for hematogenous metastases and should be
better reserved to patients most likely to recur with peritoneal-only
diffusion. On the other hand in patients more likely to recur with
hematogenous metastases adjuvant chemotherapy may represent
a more effective strategy.
In our experience the rs699947 (VEGFA, AC) polymorphism is
independently related to a higher risk of hematogenous metastasis
with an OR 8.08 (95% CI 1.7–37.5, p = 0.008). SNPs in the
promoter region of the VEGF gene have been already demon-
strated to affect patients outcome in colorectal, breast and gastric
cancer [17,30,31]. The biological interference on VEGF gene
function caused by polymorphic variants in the promoter region is
in fact likely to determine an altered expression of the gene. This
may both increase the tumour-related pro-angiogenesis potential
and ultimately guide the metastatic process through the formation
of new blood vessels [16,17,30,31]. However no data are available
about the role of VEGFs and VEGF-Rs genotyping in de-
termining the metastatic process in radically resected gastric
cancer. Most studies investigated only few SNPs potentially
involved in tumour angiogenesis, whereas in the present study
multiple SNPs in the VEGFs genes and receptors have been
globally analysed along with other known determinants.
As previously described the rs2269772 (ITGA, AA) genotype of
tumour integrins confirmed to be independently relevant in
determining peritoneal diffusion of gastric cancer cells [10). This
finding deriving from a multivariate analysis including tumour-
angiogenesis related factors strongly suggests that this specific
tumour integrin polymorphism should be considered in future
studies. On the contrary our analysis could not confirm the role of
tumour integrins in determining hematogenous diffusion. We
know from previously published analyses that upregulation of
integrins sub-classes could enhance neoplastic cells motility and
VEGF expression [32,33,34,35]. Integrins may consequently loose
their function in determining hematogenous tumour diffusion
when angiogenesis-related factors are already activated.
Tumour histology resulted a further factor independently able
to identify the gastric cancer potential to determine either
peritoneal or hematogenous metastases. Nonetheless tumour
histology alone does not seem sufficient to accurately predict the
metastatic sites. In our experience, similarly to previous reports,
a relevant proportion of patients developed peritoneal carcinosis or
hematogenous metastases independently from tumour histology.
Similar considerations could be applied to the presence of tumour
serosal involvement and/or exfoliated cancer cells in peritoneal
lavage. Not all gastric tumours with serosal infiltration will
eventually develop carcinosis and a negative peritoneal lavage
unfortunately does not exclude a future peritoneal diffusion [8,9].
We demonstrated that genotyping of rs699947 (VEGFA, AC) and
rs2269772 (ITGA, AA) have an independent role in determining
Table 3. Detailed results for tumour VEGF and VEGF-R
polymorphisms associated with either peritoneal-only
diffusion or hematogenous metastases at univariate analysis.
rs10434 (VEGFA, G.A)
GG GA AA ND
Peritoneal Carcinosis
n (%)
16 (28) 30 (53) 5 (9) 6 (10)
Hematogenous
Metastases n (%)
11 (25) 20 (46) 12 (27) 1 (2)
p n.s. n.s. 0.0282
rs699947 (VEGFA, A.C)
AA AC CC ND
Peritoneal Carcinosis
n (%)
9 (16) 17 (30) 26 (45) 5 (9)
Hematogenous
Metastases n (%)
5 (11) 26 (59) 11 (25) 2 (5)
p n.s. 0.006 n.s.
rs7993418 (FLT1, A.G)
AA AG GG ND
Peritoneal Carcinosis
n (%)
34 (60) 16 (28) 1 (2) 6 (10)
Hematogenous
Metastases n (%)
21 (48) 13 (29) 7 (16) 3 (7)
p n.s. n.s. 0.0259
ND=not done;
ns = not significant;
doi:10.1371/journal.pone.0038192.t003
Table 4. Global results for tumour VEGF and VEGF-R
polymorphisms and either peritoneal-only diffusion or
hematogenous metastases at univariate analysis.
SNP ID Gene
Peritoneal Carcinosis Or Hematogenous
Metastases
rs10434 VEGFA p= 0.0282
rs2010963 VEGFA p= 0.8
rs25648 VEGFA p= 0.5
rs3025039 VEGFA p= 0.07
rs699947 VEGFA p= 0.006
rs833061 VEGFA p= 0.08
rs4604006 VEGFC p= 0.4
rs7664413 VEGFC p= 0.09
rs664393 FLT1 p= 0.6
rs7993418 FLT1 p= 0.0259
rs1870377 KDR p= 0.06
rs2071559 KDR p= 0.2
rs2305948 KDR p= 0.09
rs7667298 KDR p= 0.1
rs307805 FLT4 p= 0.5
rs6877011 FLT4 p= 0.07
rs307822 FLT4 p= 0.06
doi:10.1371/journal.pone.0038192.t004
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the metastatic site of gastric cancer cells even when tumour
histology is included in the analysis. Our results seem then to
indicate that combining information from genotyping of rs699947,
rs2269772 and tumour histology could allow clinicians to in-
dividuate gastric cancer at high risk for recurrence either with
peritoneal or with hematogenous metastases among patients
undergoing apparent radical surgery for pT4a cancer without
exfoliated cancer cells in peritoneal lavage. In our study DNA
genotyping was performed only on tumour DNA and this may
represent a limitation for data interpretation.
Globally we believe that genotyping for specific VEGFA and
integrin genes may represent a critical asset in the definition of the
metastatic diffusion for radically resected gastric cancer patients.
Radically resected gastric cancer patients at high risk for peritoneal
recurrence may be optimal candidates for intraperitoneal therapy,
whereas if the risk of hematogenous metastases is predominant
systemic chemotherapy may represent a better option. The
selection tool deriving from this analysis may then allow an
optimal use of the available treatment strategies and should
represent a possible stratification factor in future studies in these
patients.
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